Abstract:Background: Lung adenocarcinoma (LUAD) is the most important subtype of lung cancer and usually metastasizes. Patients with LUAD usually had a poor prognosis. Identifying viable molecular markers for diagnostic and prognostic prediction among individuals with LUAD is critical for the future management of this disease. This study aimed to determine and verify a correlation between the glycolysis-related phosphoglucomutase 2 (PGM2) gene and dissatisfactory results and deficient infiltration of immune cells in LUAD.Methods: The expression of PGM2 in LUAD and adjoining normal tissues was screened from The Cancer Genome Atlas (TCGA) data and human protein atlas (HPA), and validatied by quantative reverse transcription polymerase chain reaction (qRT-PCR). We examined the correlation between PGM2 expression and clinicopathologic characteristics (including pathological stage, gender, M stage, smoker, age, N stage, race, and number pack years smoked) by multivariable approaches and Kaplan-Meier survival curves. The proteins network with PGM2 was built using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. The correlation between PGM2 expression and infiltration of immune cells, along with the corresponding gene marker sets, was investigated through the Gene Expression Profiling Interactive Analysis (GEPIA) and Tumor Immune Estimation Resource (TIMER) databases. We evaluated the possible correlation between PGM2 expression and progression-free interval (PFI), disease-specific survival (DSS), and overall survival (OS) in LUAD patients.Results: Expression of PGM2 was up-regulated in LUAD tissues (P=0.003). According to the multivariate logistic regression analysis, the elevated expression level of PGM2 exhibited a remarkable correlation with advanced tumor-node-metastasis (TNM) stage, high-grade malignancy, and primary therapeutic outcome . Overexpression of PGM2 was shown to be correlated with an unfavorable prognosis including OS (P=0.004, HR =1.54), DSS (P=0.003, HR =1.77), and PFI (P=0.003, HR =1.5) in LUAD. The proteins PGM1 and UGP2 were shown to have a significant correlation with PGM2. Additionally, PGM2 was associated with the lack of infiltrating immune cells as well as their associated gene marker sets in LUAD.Conclusions: Overexpression of PGM2 was shown to be associated with the progression and an unfavorable prognosis of LUAD, as well as with inefficient immune cell infiltration. PGM2 was expected to be a potential biological marker for predicting the prognosis of patients with LUAD.

The Prognostic Value of PKM2 and Its Correlation with Tumour Cell PD-L1 in Lung Adenocarcinoma

High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma

PKM2 is a Potential Prognostic Biomarker and Related to Immune Infiltration in Lung Cancer

Knockdown Of Pkm2 Suppresses Tumor Growth And Invasion In Lung Adenocarcinoma

Comparative Proteomic Approach Identifies PKM2 and Cofilin-1 As Potential Diagnostic, Prognostic and Therapeutic Targets for Pulmonary Adenocarcinoma.

High PKD2 predicts poor prognosis in lung adenocarcinoma via promoting Epithelial–mesenchymal Transition

Pd-L1 Expression Indicates Favorable Prognosis for Advanced Lung Adenocarcinoma Patients Treated with Pemetrexed

CKS2 Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma: A Comprehensive Study Based on Bioinformatics and Experiments

Prognostic and Predictive Values of CDK 1 and MAD 2 L 1 in Lung Adenocarcinoma

Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma

Protein Expression of Programmed Death 1 Ligand 1 and Ligand 2 Independently Predict Poor Prognosis in Surgically Resected Lung Adenocarcinoma

Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis

The Combination of PKM2 Overexpression and M2 Macrophages Infiltration Confers a Poor Prognosis for PDAC Patients

PLK1 is a Potential Prognostic Factor Associated with the Tumor Microenvironment in Lung Adenocarcinoma

F-18-Fluorodeoxyglucose Uptake Predicts Pkm2 Expression In Lung Adenocarcinoma

Overexpression of Pyruvate Kinase M2 in Tumor Tissues is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

High expression of glycolysis-related PGM2 gene in relation to poor prognosis and deficient immune cells infiltration in lung adenocarcinoma: a study based on bioinformatics analysis

LCP2 expression is correlated with an abundance of immune infiltrates and is a potential prognostic biomarker in lung adenocarcinoma

Prognostic Implication and Immunological Role of PSMD2 in Lung Adenocarcinoma

Prognostic Significance of Metabolic Enzyme Pyruvate Kinase M2 in Breast Cancer A Meta-Analysis

High expression of PKM2 as a poor prognosis indicator is associated with radiation resistance in cervical cancer